Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(20 sites)
China
Anhui Provincial Hospital(The First Affiliated Hospital of Ustc), Hefei, Anhui Fujian Cancer Hospital, Fuzhou, Fujian Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Meizhou People's Hospital（Huangtang Hospital）Meizhou Academy of Medical Sciences, Meizhou, Guangdong Ghang xi Medical University Cancer Hospital, Nanning, Guangxi Affiliated Hospital Of Hebei University, Baoding, Hebei Harbin Medical University Cancer Hospital, Harbin, Heilongjiang Anyang Cancer Hospital, Anyang, Henan The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan Xiangyang Central Hospital, Xiangyang, Hubei The First People's Hospital of Changde City, Changde, Hunan Jiangsu Province Hospital（The First Affiliated Hospital With Nanjing Medical University, Jiangsu Women And Children Health Hospital), Nanjing, Jiangsu Jiangxi Cancer Hospital, Nanchang, Jiangxi Affiliated Zhongshan Hospital Dalian University, Dalian, Liaoning Liaoning cancer hospital &institute, Shenyang, Liaoning Affiliated Zhongshan Hospital Dalian University, Jinan, Shandong Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality Shanxi Cancer Hospital, Taiyuan, Shanxi Sichuan Academy of Medical Sciences&Sichuan Provincial People's Hospital, Sichuan, Sichuan Tianjin Cancer Hospital Airport Hospital, Tianjin, Tianjin Municipality